Genentech, Inc.
South San Francisco, CA 94080-4990 (Map) Phone: 650-225-1000
Fax: 650-225-6000
http://www.gene.com
Overview
"The few, the proud, the profitable" could be Genentech's motto. One of the world's oldest and most successful biotechs (in an industry full of money-losers), the firm has a number of blockbuster cancer therapies based on its antibody (protein) technologies. Its oncology portfolio contains Rituxan, (non-Hodgkin's lymphoma); Avastin (colorectal and lung cancers); Herceptin (breast cancer); Tarceva (lung cancer); Xeloda (metastatic colorectal cancer); and Zelboraf (inoperable melanoma). Other marketed drugs include age-related macular degeneration treatment Lucentis, human growth hormone Nutropin, cystic fibrosis drug Pulmozyme, and asthma drug Xolair. Genentech is wholly owned by Swiss drugmaker Roche.
Sample Overview & HistoryKey Numbers from Hoover's UK
Key financials for Genentech, Inc.
| Company Type | Subsidiary of Roche Holding |
|---|---|
| Fiscal Year-End | December |
Key People from Hoover's UK
Key people and executives for Genentech, Inc.
| Chairman | Arthur D. (Art) Levinson (Subscribers see complete biographies -- view sample)
|
|---|---|
| CEO | Ian T. Clark |
| EVP Head Global Development and Chief Medical Officer | Hal V. Barron |
Top Competitors from Hoover's UK
Top competitors of Genentech, Inc.
There are 31 competitors for Genentech; see more.
